Soligenix, Inc. (SNGX): Operating Income
-$11.85M
Year ended 2025-12-31
-$11.04M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$11.85M | n/m | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | -$9.44M | n/m | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | -$7.70M | n/m | 2025-03-21, From 2023-01-01 |
| 2022-12-31 | -$14.24M | n/m | 2024-03-15, From 2022-01-01 |
| 2021-12-31 | -$13.10M | n/m | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | -$18.59M | n/m | 2022-03-29, From 2020-01-01 |
| 2019-12-31 | -$10.54M | n/m | 2021-03-30, From 2019-01-01 |
| 2018-12-31 | -$9.06M | n/m | 2020-03-30, From 2018-01-01 |
| 2017-12-31 | -$7.59M | n/m | 2019-03-26, From 2017-01-01 |
| 2016-12-31 | -$5.71M | n/m | 2018-03-15, From 2016-01-01 |
| 2015-12-31 | -$7.11M | n/m | 2017-03-27, From 2015-01-01 |
| 2014-12-31 | -$10.76M | n/m | 2016-03-24, From 2014-01-01 |
| 2013-12-31 | -$7.16M | n/m | 2015-03-25, From 2013-01-01 |
| 2012-12-31 | -$4.69M | n/m | 2014-03-26, From 2012-01-01 |
| 2011-12-31 | -$2.96M | n/m | 2013-02-26, From 2011-01-01 |
| 2010-12-31 | -$7.88M | n/a | 2012-03-27, From 2010-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Soligenix, Inc. (SNGX) | 2025-12-31 | -$11.85M | n/m |
| ProMIS Neurosciences Inc. (PMN) | 2025-12-31 | -$40.17M | n/m |
| Indaptus Therapeutics, Inc. (INDP) | 2025-12-31 | -$19.83M | n/m |
| Kala Bio, Inc. (KALA) | 2025-12-31 | -$39.16M | n/m |
| Can-Fite BioPharma Ltd. (CANF) | 2025-12-31 | -$9.95M | n/m |
| FibroBiologics, Inc. (FBLG) | 2025-12-31 | -$16.65M | n/m |
| Nanoviricides, Inc. (NNVC) | 2025-06-30 | -$9.59M | n/m |
| MAIA Biotechnology, Inc. (MAIA) | 2025-12-31 | -$24.27M | n/m |
| Cocrystal Pharma, Inc. (COCP) | 2025-12-31 | -$9.02M | n/m |
Compare SNGX, PMN, INDP, KALA side by side · Screen every company in Pharmaceutical Preparations ↗